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Abstract
Background: Introduction of calcineurin-inhibitor (CNI) has made transplantation a miracle in the past century. However,
the side effects of long-term use of CNI turn out to be one of the major challenges in the current century. Among these,
renal dysfunction attracts more and more attention. Herein, we undertook a meta-analysis to evaluate the efficacy and
safety of calcineurin-inhibitor (CNI) minimization protocols in liver transplant recipients with CNI-related renal dysfunction.
Methods: We included randomized trials with no year and language restriction. All data were analyzed using random effect
model by Review Manager 5.0. The primary endpoints were glomerular filtration rate (GFR), serum creatinine level (sCr) and
creatinine clearance rate (CrCl), and the secondary endpoints were acute rejection episodes, incidence of infection and
patient survival at the end of follow-up.
Results: GFR was significantly improved in CNI minimization group than in routine CNI regimen group (Z=5.45, P,0.00001;
I
2=0%). Likely, sCr level was significantly lower in the CNI minimization group (Z=2.84, P=0.005; I
2=39%). However, CrCl
was not significantly higher in the CNI minimization group (Z=1.59, P=0.11; I
2=0%). Both acute rejection episodes and
patient survival were comparable between two groups (rejection: Z=0.01, P=0.99; I
2=0%; survival: Z=0.28, P=0.78;
I
2=0%, respectively). However, current CNI minimization protocols may be related to a higher incidence of infections
(Z=3.06, P=0.002; I
2=0%).
Conclusion: CNI minimization can preserve or even improve renal function in liver transplant patients with renal
impairment, while sharing similar short term acute rejection rate and patient survival with routine CNI regimen.
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Introduction
With 1-year liver allograft survival rates now exceeding 80%
[1], attention is increasingly being paid on improving long-term
morbidity and mortality in liver transplant recipients. Renal
dysfunction is the most concerned long-term complication post-
liver transplantation, because it was estimated that 18% of
recipients would develop chronic renal failure or end-stage renal
disease by 5 years post-transplant and renal dysfunction would
significantly increase mortality risk [2–4].
Multiple factors have been reported to be involved in chronic
renal impairment in liver transplant recipients [2,4,5]. Among
these, high level exposure of calcineurin-inhibitors (CNI), namely
cyclosporin A (CsA) and tacrolimus (Tac), is a well recognized risk
factor [2,6,7]. Importantly, although chronic CNI-induced renal
insufficiency is associated with structural changes in the kidney
[8–10], an improvement in renal function can be observed in
patients after CNI reduction [11–13]. Nonetheless, the initial
attempts to withdraw CNI leaded to increased acute rejection risk
[14]. To tip the balance between potent immunosuppression and
less CNI exposure, several prospective, randomized, and con-
trolled trials (RCTs) of novel CNI minimization protocols were
conducted recently [15–23]. However, current knowledge about
these protocols is dependent on single institution studies, which
was often limited by small sample sizes and individual practice
patterns.
Herein, we performed a meta-analysis of the available literature
to better understand the efficacy and safety of CNI minimization
protocols in liver transplant patients with CNI-related renal
dysfunction. This data provide important insight capable of better
informing clinical physicians regarding the treatment of CNI-
related renal dysfunction.
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Study design, search strategy, and study selection
Before data collection, two general protocols were designed to
be compared: CNI minimization regimen and routine CNI
regimen. To limit publication bias, we included published trials
with no language or year restrictions. Initial searches of
MEDLINE, EMBASE databases and the Cochrane Database of
Systematic Reviews included terms: calcineurin-inhibitor, cyclo-
sporin A, tacrolimus or FK506, minimization, withdrawal,
reduction, elimination and liver transplantation.
To be included, trials had to be randomized, not confounded by
additional therapeutic differences between the two protocols.
Trials should compare renal function of liver transplant recipients
receiving routine CNI regimen versus CNI minimization regimen
for CNI-related renal impairment. To limit the renal function in a
comparable range, we only included patients with glomerular
filtration rate (GFR) under 60 ml/min, serum creatinine level
(sCr) more than 1.5 mg/dl or creatinine clearance rate (CrCl)
under 70 ml/min before enrollment according to the National
Kidney Foundation (NKF) recommendation for chronic kidney
disease (CKD) and the staging index used in clinical practice. To
make sure that routine CNI regimen and CNI minimization
protocols are practiced as their names, in each trial the CNI dose
in the minimization group should be initially reduced by at least
25% of the dose as is used in the routine regimen group to achieve
a lower target trough levels, or CNI were completely withdrawn
and converted to non-CNI based protocols.
Quality assessment of trials included
A quality assessment was carried out for all the retrieved RCTs.
Quality in a systematic review essentially refers to the absence of
biases. To assess the methodological validity of the studies
included in this review the following aspects were evaluated:
allocation concealment, intention to treat analysis or not, blinding
and description of handling of missing data. Articles were assessed
by two reviewers (DW and YS) independently. Disagreements
were resolved by consultation with a third reviewer (ZG).
Data extraction and outcome measures
For the trials included in our meta-analysis, we sought data for
demography information, renal function (GFR, sCr and CrCl),
acute rejection (AR), incidence of infections (including cytomeg-
alovirus (CMV), varicella zoster virus (VZV), herpes simplex
infection and nasopharyngitis, bronchitis, pneumonia, stomatitis
events and urinary tract infection (UTI)), and patient survival for
all patients. The primary outcomes of our meta-analysis were renal
function, and the secondary outcomes were AR, incidence of
various infections and patient survival. The data were extracted by
two investigators (YK and YS) independently. The conduct and
reporting were in accordance with the Quality of Reporting of
Meta-Analyses statement.
Statistical analysis
For every outcome, we used the statistical software Review
Manager 5.0 (The Cochrane Collaboration, Oxford, United
Kingdom) to analyze the collected data and to compare each
treatment group with the routine CNI regimen group. The
primary outcomes (GFR, sCr and CrCl) and the secondary
outcomes (AR, incidence of infections, patient survival) were
analyzed as continuous and dichotomized variables using random
effect model, and their results were reported as mean difference
(95% confidence interval) and odds ratio (95% confidence
interval), respectively. The statistic strength was measured by
overall effect size Z and heterogeneity index I
2.
Results
Characteristics of included studies
We included 32 trials with 1383 patients in the current meta-
analysis, including 10 RCTs [14–23] with 625 patients and 22
observational trials [12,13,24–43] with 758 patients. Figure 1
shows the flow diagram of study identification. Half of the 10
RCTs achieved CNI withdrawal or completely conversion in the
end of study [14,15,19,20,22]. For those CNI was not completely
withdrawn, MMF was started mostly at 500 mg twice a day [16–
18,23] and in one study at 1000 mg twice a day [21] and
eventually achieved 1000–2000 mg twice a day. Accordingly, CNI
dose was gradually reduced by at least 25% to reach CsA trough
level of 25–50 ng/mL or Tac trough level of 2–4 ng/mL [16–
18,23]. Since the included 32 trials used different measures of
primary outcome, we analyzed the data according to 3 different
outcome measures: GFR, sCr and CrCl. Additionally, 22
observational trials compared renal function collected at baseline
pre- and post-conversion. Although it was inappropriate to
combine these data in a meta-analysis with that of 10 RCTs,
considering these trials did follow our principle of this analysis, we
included them anyway and did a separate meta-analysis for
reference and supplement. Table 1 shows the basic characteristics
of the included studies (the first 10 were RCTs and the remaining
22 were observational studies). In general, the CNI minimization
protocols used in these 32 trials were divided into 3 categories:
mycophenolate mofetil (MMF) -based, sirolimus (SRL) -based
and everolimus (ERL) -based regimens. We compared them
both individually and collectively with the routine CNI regimen in
this meta-analysis to limit heterogeneity and gain a better
understanding of the efficacy and safety profiles of different
protocols.
Methodological quality
In general, the methodological quality of the included 10 RCTs
was not bad. However, only 3 studies described the allocation
sequences. And 3 studies used the intention-to-treat analysis to
avoid detection and attrition bias. All RCTs except one were
open-labeled study. Table 2 summarizes the risk evaluation of
bias.
CNI minimization improves renal function
Firstly, we conducted a meta-analysis of 10 RCTs regarding
GFR in patients receiving CNI minimization (including MMF
and sirolimus subgroups) versus routine CNI regimen, which was
shown in Figure 2. The forest plot graph of the comparison
showed that in MMF subgroup, GFR of recipients was
significantly higher than in routine CNI regimen group
(Z=5.16, P,0.00001; I
2=0%). While in sirolimus subgroup,
the improvement of GFR over routine CNI regimen group was
not statistically significant (Z=1.73, P=0.08;I
2 not applicable).
In total, in the included RCTs, GFR was significantly improved
in CNI minimization group as compared to routine CNI
regimen group (Z=5.45, P,0.00001; I
2=0%). Similarly, a
meta-analysis of the included observational trials regarding GFR
(shown in Figure S1) demonstrated that in MMF subgroup, GFR
was significantly higher than in the routine CNI regimen group
(Z=3.95, P,0.0001; I
2=71%). And in sirolimus subgroup, the
improvement of GFR over the routine CNI regimen group was
also significant (Z=3.17, P=0.002; I
2=90%). Collectively, in
the included observational studies, GFR was significantly
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0.0003; I
2=94%).
Then, we conducted a meta-analysis of sCr of patients
receiving CNI minimization (including MMF and sirolimus
subgroups) versus routine CNI regimen, which was shown in
Figure 3. The forest plot graph of the comparison showed that in
MMF subgroup, the sCr level of patients was significantly lower
than in routine CNI regimen group (Z=4.19, P,0.0001;
I
2=0%). While in sirolimus subgroup, the decrease of sCr level
was not statistically significant in comparison with routine CNI
regimen group (Z=0.58, P=0.56;I
2 not applicable). Collective-
ly, in the included RCTs, the sCr level was significantly decreased
in CNI minimization group (Z=2.84, P=0.005; I
2=39%). In
addition, a meta-analysis of the included observational trials
regarding sCr level (Figure S2) showed that in MMF subgroup,
the sCr level was significantly lower than in routine CNI regimen
group (Z=6.76, P,0.00001; I
2=82%). And in sirolimus
subgroup, there was a significant decrease of sCr level compared
to routine CNI regimen group (Z=7.91, P,0.00001; I
2=56%).
And in everolimus subgroup, the sCr level was also significantly
decreased (Z=2.68, P=0.007; I
2 not applicable). Totally, in the
included observational studies, the sCr level was significantly
decreased in CNI minimization group (Z=6.63, P,0.00001;
I
2=91%).
Finally, we conducted a meta-analysis of CrCl of patients
receiving CNI minimization (including MMF, sirolimus and
everolimus subgroups) versus routine CNI regimen, which was
shown in Figure 4. The forest plot graph of the comparison showed
that in MMF subgroup, the improvement of CrCl over routine CNI
regimen group was not statistically significant (Z=1.23, P=0.22;
I
2=0%). And in sirolimus subgroup, once again, we could not
document a significant improvement of CrCl (Z=1.73, P=0.08;
I
2=0%), neither did we in everolimus subgroup (Z=0.61, P=0.54;
I
2 not applicable). In total, in the included RCTs, CrCl was not
significantly improved in CNI minimization group over routine
CNI regimen group (Z=1.59, P=0.11; I
2=0%). In contrast, a
meta-analysis of the included observational trials regarding CrCl
(Figure S3) showed that in MMF subgroup, CrCl was significantly
higher than in routine CNI regimen group (Z=3.69, P=0.0002;
I
2=80%). While in everolimus subgroup, improvement of CrCl
over routine CNI regimen group was not significant (Z=1.88,
P=0.06; I
2 not applicable). Totally, in the included observational
studies, CrCl was significantly improved in CNI minimization
group (Z=4.02, P,0.0001; I
2=75%).
Figure 1. Flow diagram of study identification.
doi:10.1371/journal.pone.0024387.g001
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rejection and patient survival, but increases infection rates
To evaluate the safety of CNI minimization protocols, we then
compared acuterejection episodes,incidence of infections and patient
survival between CNI minimization and routine CNI regimen group.
For the meta-analysis of CNI minimization versus routine CNI
regimen in acute rejection, there was no significant difference
between two groups in all subgroups and total analysis (MMF
subgroup: Z=0.14, P=0.89;I
2=28%; sirolimus subgroup: Z=0.28,
P=0.78;I
2=21%; everolimus subgroup: Z=0.01, P=0.99;I
2 not
applicable; and total: Z=0.01, P=0.99;I
2=0%)(showninFigure5).
We also conducted a meta-analysis of the incidence of various
infections between two groups (shown in Figure 6). The difference
of incidence of infections between MMF/everolimus subgroup
and routine CNI regimen group was comparable (Z=1.96,
P=0.05; I
2=0%; Z=1.36, P=0.18; I
2 not applicable). While in
sirolimus subgroup, the infection incidence was significantly higher
than in routine CNI regimen group (Z=2.02, P=0.04; I
2=0%).
In total, the infection incidence was significantly higher in CNI
minimization group (Z=3.06, P=0.002; I
2=0%).
For the meta-analysis of patient survival at the end of the follow-
up, there was no significant difference between CNI minimization
and routine CNI regimen group in all subgroups and in total (MMF
subgroup:Z=0.42,P=0.67;I
2=0%;sirolimussubgroup:Z=0.59,
P=0.56; I
2 not applicable; everolimus subgroup: Z=0.47, P=0.64;
I
2 not applicable; and total: Z=0.28, P=0.78; I
2=0%) (shown in
Figure 7).
Discussion
CNI provide potent immunosuppression for solid organ
transplant patients, however, simultaneously exhibit nephrotoxicity
Table 1. Basic characteristics of the studies included in this meta-analysis.
Author Year Country
Number of
Patient
Gender
(Male/Female)
Drug Used (CNI minimiza-
tion/Routine CNI regimen)
Initial CNI trough
levels (ng/mL)
Duration of
Follow-up
H . J . S c h l i t te ta l
14 2001 Germany 28 19/9 MMF/CNI+AZA+steroids CsA 100–120/Tac 8–10 6 m
P.De Simone et al
15 2009 Italy 145 85/60 Everolimus+CNIQ+steroids/CNI* CsA 105.5/Tac 5.65 12 m
V.R.Cicinnati et al
16 2007 Germany 75 51/24 CNIQ+MMF+steroids/CNI* CsA 110.6/Tac 6.59 12 m
S.Beckebaum et al
17 2004 Germany 32 22/10 CNIQ+MMF/CNI* CsA 116/Tac 5.6 12 m
G.P.Pageaux et al
18 2006 France 56 45/11 CNIQ+MMF/CNI* CsA 162/Tac 4.4 12 m
U.Eisenberger et al
19 2009 Switzerland 16 12/4 Sirolimus*/CNI* CsA 160/Tac 10/8 12 m
C.C.Rogers et al
20 2009 U.S.A. 82 46/36 Sirolimus*/CNI* CsA 100–150/Tac 6–8 12 m
M.Biselli et al
21 2009 Italy 60 50/10 CNIQ+MMF/CNI* CsA 120/Tac 7 12 m
S.Shenoy et al
22 2007 U.S.A. 40 29/11 Sirolimus*/CNI* CsA 150/Tac 6.3 12 m
S.Beckbaum et al
23 2009 Germany 90 63/27 CNIQ+MMF/CNI* N/A 12 m
A.Kornberg et al
12 2005 Germany 43 29/14 CNIQ+MMF/CNI* CsA 143.6/Tac 9.9 6 m
M.Cantarovich et al
13 2003 Canada 19 N/A CsAQ+MMF/CsA* CsA 132 12 m
L.B.Pulido et al
24 2008 Spain 31 N/A MMF*/CNI* CsA 65.63/Tac 3.72 12 m
D.Reich et al
25 2005 U.S.A. 15 10/5 MMF+steroids/CNI* CsA 188.8/Tac 10/8 13 m
F.Di Benedetto et al
26 2009 Italy 31 N/A Sirolimus+steroids/CNI+steroids N/A 36 m
C.Ponton et al
27 2010 Spain 88 74/14 CNIQ+MMF/CNI* N/A 6 m
C.Creput et al
28 2007 France 49 37/12 CNIQ+MMF/CNI+AZA+steroids CsA 100–250/Tac 5–10 36 m
R.O.Koch et al
29 2004 Austria 32 22/10 CNIQ+MMF+steroids/CNI+AZA+steroids CsA 32/Tac 2.7 6 m
M.L.Raimondo et al
30 2003 U.K. 16 10/6 MMF*/CNI+AZA+steroids N/A 12 m
J.M.M.Planas et al
31 2004 Spain 50 32/18 MMF/CNI* CsA 93/Tac 6.5 18 m
U.Tannuri et al
32 2007 Brazil 11 5/6 CNIQ+MMF/CNI+ steroids Tac 6–8 24 m
R.Pfitzmann et al
33 2002 Germany 47 N/A CNIQ+MMF/CNI+steroids CsA 100–180/Tac 5–10 6 m
K.D.Fairbanks et al
34 2003 U.S.A. 21 10/11 Sirolimus*/CNI* N/A 16 m
E.Q.Sanchez et al
35 2005 U.S.A. 35 N/A Sirolimus+CNIQ+MMF/CNI+MMF+steroids N/A 24 m
Y.J.Yang et al
36 2008 China 16 16/0 Sirolimus*/CNI* N/A 6 m
G.Orlando et al
37 2007 Italy 42 34/8 MMF/CNI* CsA 129/Tac 2.3 12 m
P.De Simone et al
38 2009 Italy 70 51/19 Everolimus*/CNI* CsA 100–150/Tac 3–8 12 m
S.Dharancy et al
39 2009 France 52 43/9 MMF*/CNI+AZA+steroids CsA 150–250/Tac 6–12 12 m
I.Morard et al
40 2007 Switzerland 9 N/A Sirolimus*/CNI* CsA 96/Tac 7 23 m
M.Vivarelli et al
41 2010 Italy 28 N/A Sirolimus+steroids/CNI* N/A 12 m
J.Castroagudin et al
42 2011 Spain 30 26/4 Everolimus*/CNI* N/A 12 m
A.H.Cotterell et al
43 2002 U.S.A. 8 5/3 Sirolimus+CNIQ/CNI* N/A 12 m
*Regimen based on one drug with concomitant drug(s) that was either prednisone, or AZA, or MMF. Abbreviations: CNI, calcineurin inhibitor; MMF, mycophenolate
mofetil; AZA, azathioprine; N/A, not available.
doi:10.1371/journal.pone.0024387.t001
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nephrotoxicity and chronic (structural) nephrotoxicity. Whereas
acute nephrotoxicity is reversible by withdrawal of the CNI, chronic
nephrotoxicity due to CNIs is thought to be irreversible and even
progressive [44]. Withdrawal of CNI during early stages of renal
dysfunction results in improvement of renal function when
pathologic changes are still reversible [11–13]. The principle of
CNI minimization protocols is to reduce CNI exposure, by
converting CNI to non-nephrotoxic immunosuppressive drugs with
or without low dose CNI. MMF, and mammalian target of
rapamycin (mTOR) inhibitors (mTORis), namely SRL and ERL,
are the commonest options in CNI minimization protocols for their
non-nephrotoxicity and potent immunosuppression effects [14–23].
In the current meta-analysis (32 controlled studies included with
a total of 1383 patients), both GFR and sCr comparison presented
a significant improvement of renal function in CNI minimization
group in both RCTs and observational studies analysis. Although
there was significant improvement of CrCl in CNI minimization
over routine CNI regimen in observational studies, we could not
document such improvement in RCTs analysis. According to the
National Kidney Foundation recommendation, GFR is the best
estimate of kidney function and is used in the NKF staging of
CKD, thus it is rational to conclude that CNI minimization is
capable to restore renal function of liver transplant patients with
CNI-related renal impairment.
To explore whether CNI reduction is safe in liver transplant
recipients, we performed a meta-analysis of acute rejection
episodes, infection rates and patient survival. There was no
significant difference in acute rejection episodes between CNI
minimization and routine CNI regimen, suggesting the immuno-
Table 2. Risk of bias in the randomized controlled trials.
Authors
Allocation Sequence
Described
Intention To
Treat Analysis Blinding
Handling Of
Missing Data
Patient Personnel Assessor
Schlitt et al (2001)
14 No Yes Yes No No Unclear
Simone et al (2009)
15 Yes Yes No No No Unclear
Cicinnati et al (2007)
16 No Yes No No No Unclear
Beckebaum et al (2004)
17 No No No No No Unclear
Pageaux et al (2006)
18 No No No No No Unclear
Eisenberger et al (2009)
19 Y e s N o N oN oN oU n c l e a r
Rogers et al (2009)
20 No No No No No Unclear
Biselli et al (2009)
21 No No No No No Unclear
Shenoy et al (2007)
22 Y e s N o N oN oN oL a s t V a l u e F o r w a r d
Beckbaum et al (2009)
23 No No No No No Unclear
doi:10.1371/journal.pone.0024387.t002
Figure 2. Meta-analysis of CNI minimization versus routine CNI regimen in GFR (RCTs). In MMF subgroup, the GFR of recipients was
significantly higher than in routine CNI regimen group. In sirolimus subgroup, the improvement of GFR over routine CNI regimen group was not
statistically significant. In the total 10 RCTs, the GFR was significantly improved. Z=total effect size, I
2=heterogeneity index. Columns in green
represent the mean difference of each study and column size represents the study weight in the analysis. Lanes represent the 95% CI of each study.
Diamonds in black represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g002
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24387Figure 3. Meta-analysis of CNI minimization versus routine CNI regimen in sCr (RCTs). In MMF subgroup, the sCr level was significantly
lower than in routine CNI regimen group. In sirolimus subgroup, the decrease of sCr level was not statistically significant. In the total 10 RCTs, the sCr
level was significantly decreased in CNI minimization group. Z=total effect size, I
2=heterogeneity index. Columns in green represent the mean
difference of each study and column size represents the study weight in the analysis. Lanes represent the 95% CI of each study. Diamonds in black
represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g003
Figure 4. Meta-analysis of CNI minimization versus routine CNI regimen in CrCl (RCTs). In MMF, sirolimus and everolimus subgroup, the
improvement of CrCl over routine CNI regimen group was not statistically significant, as well as in the total 10 RCTs. Z=total effect size,
I
2=heterogeneity index. Columns in green represent the mean difference of each study and column size represents the study weight in the analysis.
Lanes represent the 95% CI of each study. Diamonds in black represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g004
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minimization. However, the incidence of infections is higher in CNI
minimization group than in routine CNI group, although most
studies did not provide the exact incidence of specific infections,
suggesting increased immune load by CNI minimization protocols
when introducing MMF or mTORis. On the other hand, there was
no significant difference in patient survival between two groups,
which can be interpreted in three ways. Firstly, the follow-up
durationsofthesestudiesarenotlongenoughtoshowanychange of
the survival rate. Secondary, the improvement in renal function is
not sufficient enough to alter patient survival [45]. Finally, the renal
benefit may be counteracted by the increased infection risks.
Therefore, whether the improved renal function can be translated
into a better survival and whether long term use of CNI
minimization protocols would lead to a higher acute rejection or
infection rate still need further study.
Notably, the CNI minimization protocols in the included studies
are heterogenous. Since the additional drugs and different
combinations can alter the outcomes, we divided them into 3
subgroups, namely MMF-based, SRL-based and ERL-based
subgroups. In both meta-analysis of RCTs and observational
trials, the MMF-based regimen presents an obvious benefit on
renal function protection. It has been reported that replacement of
CNI by MMF in liver transplant patients with renal dysfunction
can also improve other CNI associated side-effects, such as
hypertension and hyperuricemia [46]. Concern about this CNI
minimization protocol is from the fact that there are conflicting
results regarding the risk of allograft rejection with withdrawal of
CNI and subsequent MMF monotherapy [14,29,47–50]. Howev-
er, in the current meta-analysis, MMF-based CNI minimization
protocol is not associated with higher rejection and infection rates.
One of the major reasons explaining the discrepancy of rejection
rate between the previous reports and current analysis is that most
recent protocols are combination of MMF and low-dose CNI but
not MMF monotherapy. Collectively, we recommend that MMF
can serve as a good option to reduce CNI exposure in liver
transplant recipients with renal dysfunction, without increasing
rejection and infection rates.
In addition, mTORis are potent anti-proliferative agents that
have clear therapeutic potential in liver transplantation [51–55].
However, only 4 SRL-based RCTs were included in this meta-
analysis, and no significant improvement of renal function was
documented, neither did the ERL-based RCTs. But in the meta-
analysis of observational trials, SRL-based regimen yielded a
Figure 5. Meta-analysis of CNI minimization versus routine CNI regimen in acute rejection (RCTs). There was no significant difference
between CNI minimization and routine CNI regimen group in all subgroup and total analysis. Z=total effect size, I
2=heterogeneity index. Columns in
blue represent the odds ratio of each study and column size represents the study weight in the analysis. Lanes represent the 95% CI of each study.
Diamonds in black represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g005
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sCr, in spite of relatively high heterogeneities. Both SRL-based
and ERL-based regimens are equally potent and safe as routine
CNI regimen in immunosuppression according to our meta-
analysis. Moreover, in non-renal dysfunction population, SRL,
either used in combination with prednisone alone or MMF-
prednisone in CNI-withdrawal protocols, resulted in improved
renal function and acceptable acute rejection rate, although with
increased rates of thrombocytopenia, digestive hemorrhage,
pleural effusion and other adverse events [56]. In terms of ERL,
Simone et al recently reported that ERL, in combination with low-
dose CNI, was associated with low acute rejection rate and
particularly good renal function [15]. However, in another study,
the use of combination CsA and mTORis leaded to potential long-
term CNI nephrotoxicity [57]. Since the number of SRL-based
and ERL-based RCTs included in this meta-analysis is small,
more high-quality RCTs based on SRL and ERL should be
conducted to draw a clear conclusion on whether mTORis-based
CNI minimization protocols are effective and safe in patients with
impaired renal function. However, according to the results from
the meta-analysis of observational trials and considering their well
known anti-tumor effects [58–60], mTORis may be a good
alternative for MMF to reduce or replace CNI in liver transplant
recipients with a pre-transplant diagnosis of hepatocellular
carcinoma (HCC) and post-transplant renal dysfunction. Howev-
er, clinicians should pay attention to the increased risks of
infections when SRL is used.
Undoubtedly, there are some limitations in the current meta-
analysis as others. Firstly, we included studies using different
regimens without comparing between themselves, it make us
difficult to figure out which combination is the best one although
the current data show that the MMF-based CNI minimization
protocol received the greatest supports. Secondly, most of the
studies we included didn’t undertake follow-ups longer than 12
months, giving us insufficient data on how CNI minimization
would affect long-term graft or patient survival. Finally, as shown
in Table 2, the risk of bias of the included randomized trials was
relatively high, since no study was double blind designed and only
3 of 10 studies conducted intention-to-treat analysis, which may
attenuate the power of the current study.
In conclusion, this meta-analysis included all current relevant
studies from various countries covering different populations. It
Figure 6. Meta-analysis of CNI minimization versus routine CNI regimen in infection incidence (RCTs). In MMF and everolimus
subgroup, the difference of infection incidence was not statistically significant. In sirolimus subgroup, the infection incidence was significantly higher
than in routine CNI regimen group. In total, the infection incidence was significantly higher in CNI minimization group. Z=total effect size,
I
2=heterogeneity index. Columns in blue represent the odds ratio of each study and column size represents the study weight in the analysis. Lanes
represent the 95% CI of each study. Diamonds in black represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g006
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population of individual studies, providing stronger evidence on
the clinical application of CNI minimization protocols. It is
convincing that CNI minimization can improve renal function in
liver transplant patients with CNI-related renal impairment, while
has an equal or similar effect on acute rejection and patient
survival as routine CNI regimen. However, it should be cautious to
use SRL-based minimization regimens in patients with high risks
of infections. Studies in the future should try to figure out whether
this improved renal function can prolong long-term patient or
graft survival, and which minimization protocol is the standard
one in various combinations.
Supporting Information
Figure S1 Meta-analysis of CNI minimization versus
routine CNI regimen in GFR (observational trials). In
MMF and sirolimus subgroups, GFR was significantly higher
than in the routine CNI regimen group, so was in the total
analysis. Z=total effect size, I
2=heterogeneity index. Columns
in green represent the mean difference of each study and column
size represents the study weight in the analysis. Lanes represent
the 95% CI of each study. Diamonds in black represent the
overall effect size and diamond width represents the overall 95%
CI.
(TIF)
Figure S2 Meta-analysis of CNI minimization versus
routine CNI regimen in sCr (observational trials). In
MMF, sirolimus and everolimus subgroups, the SCr was
significantly decreased in CNI minimization group, so was in the
total analysis. Z=total effect size, I
2=heterogeneity index.
Columns in green represent the mean difference of each study
and column size represents the study weight in the analysis. Lanes
represent the 95% CI of each study. Diamonds in black represent
the overall effect size and diamond width represents the overall
95% CI.
(TIF)
Figure S3 Meta-analysis of CNI minimization versus
routine CNI regimen in CrCl (observational trials). In
MMF subgroup, CrCl was significantly higher in the CNI
minimization group than in the routine CNI regimen group. In
everolimus subgroup, improvement of CrCl over routine CNI
regimen group was not statistically significant. In the total analysis,
the CrCl was significantly improved in CNI minimization group.
Z=total effect size, I
2=heterogeneity index. Columns in green
Figure 7. Meta-analysis of CNI minimization versus routine CNI regimen in patient survival (RCTs). There was no significant difference
between CNI minimization and routine CNI regimen group in all subgroup and total analysis. Z=total effect size, I
2=heterogeneity index. Columns in
blue represent the odds ratio of each study and column size represents the study weight in the analysis. Lanes represent the 95% CI of each study.
Diamonds in black represent the overall effect size and diamond width represents the overall 95% CI.
doi:10.1371/journal.pone.0024387.g007
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represents the study weight in the analysis. Lanes represent the
95% CI of each study. Diamonds in black represent the overall
effect size and diamond width represents the overall 95% CI.
(TIF)
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